相关临床试验
10
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
10.0%
已完成
3
30.0%
尚未招募
2
20.0%
招募中
4
40.0%
暂无批准数据
- Mondego Bio has selected ZE00-0388, a highly selective PTPN2 inhibitor, as its lead clinical candidate following extensive preclinical evaluation demonstrating favorable safety and tolerability profiles. - The company plans to initiate first-in-human Phase 1 trials in the first half of 2026, featuring a dual-track design with healthy volunteers and oncology patients. - ZE00-0388 is an AI-designed small-molecule that targets PTPN2, an intracellular regulator of cytokine and interferon signaling pathways within the tumor microenvironment. - The clinical program will evaluate the drug both as monotherapy and in combination with immune checkpoint inhibitors in patients with solid tumors.
- Eilean Therapeutics presented preclinical data for TE205, a first-in-class MALT1 degrader, demonstrating robust immunomodulatory effects in DSS-induced colitis models at the 4th International Conference on Microbiology and Immunology. - The compound achieved structural and functional restoration of intestinal integrity by selectively degrading MALT1, suppressing NF-κB signaling, and rebalancing immune cell populations within the lamina propria. - TE205 showed disease-modifying potential for inflammatory bowel disease by restoring epithelial barrier function and mucosal architecture, establishing it as a promising therapeutic candidate for ulcerative colitis treatment.
- Eilean Therapeutics presented data on ZE77-0273, a brain- and lung-permeable pan-EGFR inhibitor designed to overcome resistance mutations in EGFR-mutant non-small cell lung cancer. - The reversible small-molecule drug candidate demonstrates broad activity against resistance mutations while maintaining high selectivity versus wild-type EGFR. - ZE77-0273 exhibits a wide therapeutic window with excellent safety and tolerability profiles, potentially addressing a critical unmet need in therapy-resistant lung cancer. - The company utilizes a proprietary hybrid AI/ML drug design platform to develop best-in-class and first-in-class small molecule inhibitors targeting escape mutations in cancer.
- Mondego Bio, a Portuguese biotech startup, has secured Series A funding led by Biovance Capital Partners alongside OrbiMed and Torrey Pines Investment to develop PTPN2 inhibitors for cancer treatment. - The company is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors that could improve cancer immunotherapy efficacy with enhanced safety profiles. - PTPN2 functions as a critical negative regulator of the JAK-STAT pathway, and its inhibition represents a potential therapeutic strategy to enhance interferon-gamma signaling in cancer immunotherapy. - This investment marks the inaugural funding from Biovance Capital Fund I, which manages €57 million to support early-stage drug development companies across Europe.
